Igor Tsaur, Director and Chairman, Department of Urology at University Hospital Tübingen, shared a post on LinkedIn:
“Happy to announce the beginning of the initiation of the study centers of our DEPECA-1 trial – Investigator Initiated Trial from the Department of Urology, Eberhard-Karls-University of Tübingen, sponsored by IKF – The Frankfurt Institute of Clinical Cancer Research and funded by Merck Group and Astellas Pharma.
In this phase-2 trial male patients with surgically incurable locally advanced and/or metastasized penile cancer will be offered combination therapy with enfortumab vedotin and avelumab. We anticipate initiating patient inclusion from December 2025. Eagerly awaiting the results and hoping to finally improve life expectancy in this disease. Use this unique opportunity and refer patients to your nearest study site.”
More posts on OncoDaily.